GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » EPS without NRI

IDEXX Laboratories (IDEXX Laboratories) EPS without NRI

: $10.12 (TTM As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

IDEXX Laboratories's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $2.34. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $10.12.

During the past 12 months, IDEXX Laboratories's average earnings per share (NRI) Growth Rate was 26.30% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 14.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 19.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for IDEXX Laboratories's EPS without NRI or its related term are showing as below:

IDXX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.1   Med: 17.6   Max: 139
Current: 14.8

During the past 13 years, IDEXX Laboratories's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 139.00% per year. The lowest was -47.10% per year. And the median was 17.60% per year.

IDXX's 3-Year EPS without NRI Growth Rate is ranked better than
65.9% of 173 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.2 vs IDXX: 14.80

IDEXX Laboratories's EPS (Diluted) for the three months ended in Dec. 2023 was $2.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $10.07.

IDEXX Laboratories's EPS (Basic) for the three months ended in Dec. 2023 was $2.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $10.17.


IDEXX Laboratories EPS without NRI Historical Data

The historical data trend for IDEXX Laboratories's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 4.89 [6] => 6.71 [7] => 8.60 [8] => 8.03 [9] => 10.14 )
IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.89 6.71 8.60 8.03 10.14

IDEXX Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.07 2.55 2.70 2.53 2.34

Competitive Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories PE Ratio without NRI Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's PE Ratio without NRI falls into.



IDEXX Laboratories EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEXX Laboratories  (NAS:IDXX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


IDEXX Laboratories EPS without NRI Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories (IDEXX Laboratories) Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Executives
James F Polewaczyk officer: Corporate Vice President IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky director, officer: President and CEO ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith officer: Executive Vice President C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers director, officer: President & CEO IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane officer: Executive Vice President C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt director CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin director 7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley director C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak director C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg officer: EVP, GC & Corporate Secretary EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek director 6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451

IDEXX Laboratories (IDEXX Laboratories) Headlines